Evidence Snapshot

Alpha-1B adrenergic receptor

CHEMBL232 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:22Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 6:24 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL232

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Alpha-1B adrenergic receptor as ChEMBL target CHEMBL232, mapped to UniProt P35368. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Alpha-1B adrenergic receptor

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL232

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P35368

Alpha-1B adrenergic receptor

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Alpha-1B adrenergic receptor matters

As of 2026-09-13

Alpha-1B adrenergic receptor is reviewed as Alpha-1B adrenergic receptor (UniProt P35368); the current evidence base includes 45 approved drugs, 2517 compounds, and 429 assays, with lead potency reaching pChEMBL 10.6.

Protein context

Alpha-1B adrenergic receptor

Alpha-1B adrenergic receptor Sequence length is 520 aa.

Review this target as Alpha-1B adrenergic receptor, mapped to UniProt P35368. Sequence length is 520 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P35368 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 45 approved drugs, 2517 compounds, and 429 assays for this target. The dominant activity type is KI. CHEMBL2 is the current potency anchor at pChEMBL 10.6.

Use CHEMBL2 as the tractability anchor when discussing potency (pChEMBL 10.6).

Activity source · ChEMBL 36 via Core Engine

45 approved pChEMBL 10.6

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Alpha-1B adrenergic receptor matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P35368, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2517

Total Compounds

429

Total Assays

Approved Drugs

IC50: 202.0, KI: 1849.0, EC50: 269.0, KD: 13.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL2	10.6	Ki	Approved
No preferred name CHEMBL25554	10.4	Ki	—
No preferred name CHEMBL42472	10.4	Ki	—
No preferred name CHEMBL342062	10.2	Ki	—
No preferred name CHEMBL324090	10.1	Ki	Clinical

Approved Drugs

Structure	Compound	First Approval
	LUMATEPERONE TOSYLATE CHEMBL3233142	2019
	BREXPIPRAZOLE CHEMBL2105760	2015
	SILODOSIN CHEMBL24778	2008
	ALFUZOSIN CHEMBL709	2003
	ARIPIPRAZOLE CHEMBL1112	2002
	NAFTOPIDIL CHEMBL142635	1999
	TAMSULOSIN CHEMBL836	1997
	QUETIAPINE CHEMBL716	1997
	AZELASTINE CHEMBL639	1996
	OLANZAPINE CHEMBL715	1996
	NEFAZODONE HYDROCHLORIDE CHEMBL1200492	1994
	RISPERIDONE CHEMBL85	1993
	DOXAZOSIN CHEMBL707	1990
	CLOZAPINE CHEMBL42	1989
	TERAZOSIN CHEMBL611	1987
	OXYMETAZOLINE CHEMBL762	1986
	PRAZOSIN HYDROCHLORIDE CHEMBL1558	1976
	PRAZOSIN CHEMBL2	1976
	EPINEPHRINE CHEMBL679	1965
	PHENTOLAMINE CHEMBL597	1952
	PHENYLEPHRINE CHEMBL1215	1952
	DIHYDROERGOTAMINE MESYLATE CHEMBL1200517	1946

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:22Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 6:24 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL232